| Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma W Wu, TD Bhagat, X Yang, JH Song, Y Cheng, R Agarwal, JM Abraham, ... Gastroenterology 144 (5), 956-966. e4, 2013 | 269 | 2013 |
| IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells C Schinke, O Giricz, W Li, A Shastri, S Gordon, L Barreyro, T Bhagat, ... Blood, The Journal of the American Society of Hematology 125 (20), 3144-3152, 2015 | 179 | 2015 |
| Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts TD Bhagat, D Von Ahrens, M Dawlaty, Y Zou, J Baddour, A Achreja, ... Elife 8, e50663, 2019 | 116 | 2019 |
| The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes BH Yip, V Steeples, E Repapi, RN Armstrong, M Llorian, S Roy, J Shaw, ... The Journal of clinical investigation 127 (6), 2206-2221, 2017 | 99 | 2017 |
| Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β A Agarwal, K Morrone, M Bartenstein, ZJ Zhao, A Verma, S Goel Stem cell investigation 3, 2016 | 99 | 2016 |
| Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model AM Marcondes, X Li, L Tabellini, M Bartenstein, J Kabacka, GE Sale, ... Blood, The Journal of the American Society of Hematology 118 (18), 5031-5039, 2011 | 83 | 2011 |
| Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells A Shastri, G Choudhary, M Teixeira, S Gordon-Mitchell, N Ramachandra, ... The Journal of clinical investigation 128 (12), 5479-5488, 2018 | 77 | 2018 |
| ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts S Valletta, H Dolatshad, M Bartenstein, BH Yip, E Bello, S Gordon, Y Yu, ... Oncotarget 6 (42), 44061, 2015 | 75 | 2015 |
| North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies UA Shah, EY Chung, O Giricz, K Pradhan, K Kataoka, S Gordon-Mitchell, ... Blood, The Journal of the American Society of Hematology 132 (14), 1507-1518, 2018 | 73 | 2018 |
| Epigenetically aberrant stroma in MDS propagates disease via Wnt/β-catenin activation TD Bhagat, S Chen, M Bartenstein, AT Barlowe, D Von Ahrens, ... Cancer research 77 (18), 4846-4857, 2017 | 70 | 2017 |
| Hematopoietic stem cell transplantation for MDS M Bartenstein, HJ Deeg Hematology/Oncology Clinics 24 (2), 407-422, 2010 | 50 | 2010 |
| Efficacy of ALK5 inhibition in myelofibrosis L Yue, M Bartenstein, W Zhao, WT Ho, Y Han, C Murdun, AW Mailloux, ... JCI insight 2 (7), 2017 | 48 | 2017 |
| Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia L Bachegowda, K Morrone, SL Winski, I Mantzaris, M Bartenstein, ... Cancer research 76 (16), 4841-4849, 2016 | 42 | 2016 |
| Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes S Sundaravel, R Duggan, T Bhagat, DL Ebenezer, H Liu, Y Yu, ... Proceedings of the National Academy of Sciences 112 (46), E6359-E6368, 2015 | 37 | 2015 |
| The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma O Giricz, Y Mo, KB Dahlman, XM Cotto-Rios, C Vardabasso, H Nguyen, ... JCI insight 3 (14), 2018 | 36 | 2018 |
| High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster S Jasra, O Giricz, R Zeig-Owens, K Pradhan, DG Goldfarb, ... Nature medicine 28 (3), 468-471, 2022 | 25 | 2022 |
| Beneficial and hindering factors for psychotherapy utilization and treatment outcome in personality disorders. Part 1: Diagnostic procedures relevant for psychotherapy planning … H Löffler-Stastka, E Ponocny-Seliger, M Szerencsics, M Bartenstein, ... New research on personality disorders. New York: Nova Science Publishers Inc …, 2008 | 10* | 2008 |
| Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status HJ Deeg, M Bartenstein Archivum immunologiae et therapiae experimentalis 60, 31-41, 2012 | 9 | 2012 |
| Preclinical efficacy of TGF-beta receptor I kinase inhibitor, galunisertib, in myelofibrosis L Yue, M Bartenstein, W Zhao, WT Ho, L Zhang, F Rapaport, RL Levine, ... Blood 126 (23), 603, 2015 | 7 | 2015 |
| Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions TG Bowler, K Pradhan, Y Kong, M Bartenstein, KA Morrone, A Sridharan, ... Leukemia & Lymphoma 60 (13), 3132-3137, 2019 | 6 | 2019 |
